J.B. Chemicals & Pharmaceuticals Ltd.
NSE: JBCHEPHARMJ.B. Chemicals & Pharmaceuticals Ltd.: A 30-second snapshot
JBCHEPHARM trades at ₹2408.9, up 45.1% over the past year and 18.37% over the past 3 months, sitting 4.62% below its 52-week high and above both its 50-DMA (₹2269.24) and 200-DMA (₹1979.33). It carries a trailing PE of 54.22x (forward 32.78x) against an ROE of 18.69% and a 5-year earnings CAGR of -31%. Mean analyst rating stands at 1.5 across 8 analysts (1-5 scale, lower = more constructive).
P/E
54.2
Forward P/E
32.8
ROE
+18.7%
Debt / Equity
0.09
Profit Margin
+17.1%
Div. Yield
+0.8%
5Y ROE > 15%
4/5
5Y FCF > 0
3/5
Quality
62/100
News
1 headlines · 0 positive · 0 negative
Recent context
- ·The most recent captured headline (July 30, 2026, marketscreener.com) covered analyst target-price consensus and was tagged neutral; no other news items were captured in this run.
- ·News sample size is thin — 1 article total — limiting confidence in any sentiment read for the stock this period.
- ·Mean analyst rating stands at 1.5 across 8 analysts (1-5 scale, lower = more constructive).
Strengths
- +ROE of 18.69% with 4 of the tracked years above 15% and a persistence consistency score of 81/100.
- +Debt-to-equity of 0.086x is among the lowest leverage profiles in the tracked peer set, with a falling debt trend.
- +Price is up 45.1% over 12 months and trades above both the 50-DMA and 200-DMA, only 4.62% below its 52-week high.
- +ROE ranks 2nd of 6 tracked pharma peers, trailing only Apollo Hospitals (21.5%).
Weaknesses
- −5-year earnings growth of -31% and 5-year revenue growth of -4.8% show the trailing growth trend has been negative despite current profitability.
- −Trailing PE of 54.22x is above 3 of the 5 tracked peers (Dr. Reddy's 28.84x, Cipla 35.11x, Sun Pharma 42.08x) and ranks 4th of 6 on sector valuation.
- −FCF was positive in only 3 of the years covered in the persistence dataset, versus ROE above 15% in 4 of those years — profitability has not been fully mirrored in cash generation.
- −Quality score of 32 ranks 4th of 6 tracked pharma peers, below Sun Pharma (56), Apollo Hospitals (44) and Max Healthcare (37).
Open questions
- ?Does the negative 5-year earnings and revenue growth reflect one-off items or a more structural slowdown in the underlying business?
- ?How does the 54.22x trailing PE (versus 32.78x forward) reconcile with a five-year earnings CAGR of -31%?
- ?What explains the gap between JBCHEPHARM's low leverage (D/E 0.086x) and its mid-pack quality score (32, rank 4 of 6) relative to peers?
- ?With only 1 news article captured in this run, what other disclosures or filings might help explain the 45.1% one-year price move?
Peer comparison: Pharma
Ranks 4 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| JBCHEPHARM | J.B. Chemicals & Pharmaceuticals Ltd.You're viewing | 54.2 | +18.7% | 32 |
| Industry avg | across 5 peers | 49.4 | +14.8% | 34 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 42.1 | +14.7% | 56 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 66.2 | +21.5% | 44 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 74.8 | +14.3% | 37 |
| CIPLA | Cipla Ltd. | 35.1 | — | 28 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 28.8 | +8.8% | 4 |
Technical state
Current price
₹2,408.90
SMA 50
₹2,269.24
SMA 200
₹1,979.33
RSI (14)
61.1 (neutral)
From 52w high
-4.6%
1Y return
+45.1%
3M return
+18.4%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- medium5-year earnings growth stands at -31% and 5-year revenue growth at -4.8%, indicating the trailing growth trend has been negative even though current ROE (18.69%) and profit margin (17.11%) remain healthy.
- mediumTrailing PE of 54.22x sits above 3 of the 5 tracked pharma peers (Dr. Reddy's 28.84x, Cipla 35.11x, Sun Pharma 42.08x) and ranks 4th of 6 on sector PE; forward PE compresses to 32.78x, implying an earnings recovery not evidenced in the trailing 5-year trend.
- lowQuality score of 32 ranks 4th of 6 tracked pharma peers, below Sun Pharma (56), Apollo Hospitals (44) and Max Healthcare (37).
- lowNews sample totals just 1 article for this run, too thin to draw a reliable sentiment reading.
Cross-section contradictions
- Trailing PE of 54.22x sits near the top of the sector range while 5-year earnings growth (-31%) and 5-year revenue growth (-4.8%) are both negative — the stock is priced at a premium multiple despite a trailing record of earnings and revenue contraction.
- Mean analyst rating of 1.5 across 8 analysts (1-5 scale, lower = more constructive) sits at the constructive end of the scale, yet trailing 5-year earnings and revenue growth are both negative, suggesting coverage is weighted toward a forward recovery not visible in the trailing data.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 11 Aug 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 31 Jul 2026 · rotates through NIFTY 500 every ~5 days